Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-DOTATATE in Neuroendocrine Neoplasms
NCT01237457Phase 2Completed
- Start
- Oct 2010
- Primary completion
- Nov 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lutetium Lu 177 dotatate in neuroendocrine tumors (NETs). Started Oct 2010; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
neuroendocrine tumors (NETs)
Beyond the preview
Go deeper on NCT01237457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01237457.